# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k091284   
B. Purpose for Submission: To obtain clearance for the VisuCal-F frozen calibrator plasma, VisuCon-F frozen normal control plasma and VisuCon-F frozen abnormal control plasma   
C. Measurand: Normal and Abnormal Control Plasma: Fibrinogen (Clauss Method), coagulation factors II, V, VII, VIII, IX, X, XI and XII, antithrombin activity, protein S activity and protein C activity. Calibrator plasma: Fibrinogen (Clauss Method), coagulation factors II, V, VII, VIII, IX, X, XI and XII, anti-thrombin activity, α-2-antiplasmin, plasminogen, protein C activity and antigen, protein S activity and total antigen, von Willebrand factor antigen and ristocetin cofactor.   
D. Type of Test: Assayed Controls and Calibrator   
E. Applicant: Affinity Biologicals, Inc.   
F. Proprietary and Established Names: VisuCal-F frozen calibrator plasma VisuCon-F frozen normal control plasma VisuCon-F frozen abnormal control plasma

# G. Regulatory Information:

1. Regulation section: 21 CFR 864.5425; Multipurpose systems for in vitro coagulation studies   
2. Classification: Class II   
3. Product code: GGN; Plasma, Coagulation Control JIX; Calibrator, Multi-Analyte Mixture   
4. Panel: Hematology 81

# H. Intended Use:

1. Intended use(s): The VisuCal-F frozen calibrator plasma is intended for use in the calibration of coagulation and fibrinolysis assays. The VisuCon-F frozen normal control plasma is intended for use in the quality control of coagulation assays in the normal range. The VisuCon-F frozen abnormal control plasma is intended for use in the quality control of coagulation assays in the borderline pathological range.

# 2. Indication(s) for use:

The VisuCal-F frozen calibrator plasma is intended for use in the calibration of coagulation and fibrinolysis assays including the following: Fibrinogen (Clauss

Method), Coagulation factors II, V, VII, VIII, IX, X, XI and XII, anti-thrombin activity, $\mathfrak { a }$ -2-antiplasmin, plasminogen, protein C activity and antigen, protein S activity and total antigen, von Willebrand factor antigen and ristocetin cofactor.

The VisuCon-F frozen normal control is intended for use in the quality control of coagulation assays in the normal range for the following parameters: Fibrinogen (Clauss Method), Coagulation factors II, V, VII, VIII, IX, X, XI and XII, antithrombin activity, protein S activity and protein C activity.

The VisuCon-F frozen abnormal control is intended for use in the quality control of coagulation assays in the borderline pathological range for the following parameters: Fibrinogen (Clauss Method), Coagulation factors II, V, VII, VIII, IX, X, XI and XII, antithrombin activity, protein S activity and protein C activity.

3. Special conditions for use statement(s): Not Applicable   
4. Special instrument requirements: Not Applicable

I. Device Description:

The VisuCal-F frozen calibrator plasma, VisuCon-F frozen normal control plasma, and VisuCon-F frozen abnormal control plasma are pools of normal citrated human plasma collected from a minimum of 20 donors, buffered with $0 . 0 2 { \bf M }$ HEPES buffer, dispensed and rapidly frozen.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dade Behring standard human plasma Precision Biologic Reference Check normal control plasma Precision Biologic Cryocheck abnormal reference check I & II

2. Predicate K number(s): k023141 k013708 k952624   
3. Comparison with predicate:

<table><tr><td colspan="4" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">Additional Predicate</td></tr><tr><td colspan="1" rowspan="1">Device name</td><td colspan="1" rowspan="1">VisuCal-F frozen calibratorplasma (k091284)</td><td colspan="1" rowspan="1">Dade Behring StandardHuman Plasma(k023141)</td><td colspan="1" rowspan="1">Precision Biologic CryocheckNormal Reference Plasma(k952622)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For use in the calibration ofcoagulation and fibrinolysisassays</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">For use in the in vitroquantification of hemostaticparameters in human plasma.May also be used to assignvalues to in-house collectednormal plasma pools or tocommercially availableunassayed frozen plasmapools.</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Citrated human plasma</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability of</td><td colspan="1" rowspan="1">Value assignments</td><td colspan="1" rowspan="1">Value assignments</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">calibratorplasma</td><td colspan="1" rowspan="1">traceable to SSC/ISTHsecondary coagulationstandard, where available,which is calibrated againstWHO Internationalstandards</td><td colspan="1" rowspan="1">traceable to WHOInternational standards,where available</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Fibrinogen, factors II, V,VII, VIII, IX, X, XI andXII von Willebrand factorantigen, ristocetin cofactor,protein S activity, protein Cactivity, anti-thrombinactivity, α-2-antiplasmin,plasminogen, Protein Cantigen and protein S totalantigen</td><td colspan="1" rowspan="1">Fibrinogen, factors II, V,VII, VIII IX, X, XI andXII, von Willebrandfactor antigen, ristocetincofactor, protein Sactivity, protein Cactivity, anti-thrombinactivity, α-2-antiplasmin,plasminogen</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=6>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=2>Device</td><td rowspan=1 colspan=2>Predicate</td><td rowspan=1 colspan=1>Additional Predicate</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Prothrombin time (PT),factor XIII, C-1 inhibitor,Total complement activity</td><td rowspan=1 colspan=1>Factor XIII, Free Protein Santigen, antithrombinantigen</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=2>Frozen</td><td rowspan=1 colspan=2>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Open vialstability</td><td rowspan=1 colspan=2>8 hours at 28°C exceptprotein S which is stable for4 hours at 28°C</td><td rowspan=1 colspan=2>4 hours at 15 to 25°C, 4weeks at -20°C</td><td rowspan=1 colspan=1>8 hours at 28°C</td></tr><tr><td rowspan=1 colspan=2>Open vial stability</td><td rowspan=1 colspan=2>8 hours at 28°C</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>Traceability of</td><td rowspan=1 colspan=2>/ISTH</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>calibratortglasma</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=2>Device Name</td><td rowspan=1 colspan=2>jsuC on-F frozen normal control plasmaWHO Internatonal standards</td><td rowspan=1 colspan=2>Precision Biologic Reference Check</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>VisuCon-F frozen abnormal controlplasma</td><td rowspan=1 colspan=2>Normal Control (k013708)Precision Biologic Abnormal 1Reference Control (k952624)</td></tr><tr><td rowspan=1 colspan=2>Intended Use</td><td rowspan=1 colspan=2>VisuCon-F frozen normal control plasma:For the quality control of coagulationassays in the normal range.VisuCon-F frozen abnormal controlplasma: For the quality control ofcoagulation assays in the borderlinepathological range.</td><td rowspan=1 colspan=2>Precision Biologic Reference NormalControl: For controlling the accuracyof quantitative hemostasis assays in thenormal range.Precision Biologic Abnormal 1Reference Control: For controlling theaccuracy of quantitative hemostasisassays in the normal range.</td></tr><tr><td rowspan=1 colspan=2>Matrix</td><td rowspan=1 colspan=2>Citrated human plasma</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>Format</td><td rowspan=1 colspan=2>Frozen</td><td rowspan=1 colspan=2>Same</td></tr><tr><td rowspan=1 colspan=2>Analytes</td><td rowspan=1 colspan=2>Fibrinogen, factors II, V, VII, VIII, IX, X,XI and XII, protein S activity, protein Cactivity, anti-thrombin activity</td><td rowspan=1 colspan=2>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>VisuCon-F frozen normal control plasmaVisuCon-F frozen abnormal controlplasma</td><td rowspan=1 colspan=1>Precision Biologic reference controlnormalPrecision Biologic abnormal 1reference control</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Factor XIII, von Willebrand factorantigen, ristocetin cofactor,Prekallikrein, protein S total antigen,free antigen, protein C antigen, anti-thrombin antigen, α-2-antiplasmin,plasminogen</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Points to consider: Guidance for Industry and FDA Staff - Assayed and Unassayed Quality Control Material, February 3, 1999.

# L. Test Principle:

The VisuCal-F frozen calibrator plasma is an assayed reference plasma prepared from a pool of citrated human plasma collected from a minimum of 20 donors, buffered with 0.02M HEPES buffer, dispensed and rapidly frozen. The plasma can be used to construct a reference curve when measuring the following parameters: Fibrinogen (Clauss Method), coagulation factors II, V, VII, VIII, IX, X, XI and XII, anti-thrombin activity, $\mathfrak { a } \mathrm { . }$ -2-antiplasmin, plasminogen, protein C activity and antigen, protein S activity and total antigen, von Willebrand factor antigen and ristocetin cofactor.

The VisuCon-F frozen normal control plasma is a pool of normal citrated human plasma collected from a minimum of 20 donors, buffered with 0.02M HEPES buffer, dispensed and rapidly frozen. This control plasma may be used to confirm assay calibration and to monitor the performance of coagulation assays for the following parameters: fibrinogen (Clauss Method), coagulation factors II, V, VII, VIII, IX, X, XI and XII, anti-thrombin, protein C and protein S.

The VisuCon-F frozen abnormal control plasma is a pool of 20 normal citrated human plasma donors, diluted to defined concentrations, buffered with 0.02M HEPES buffer, dispensed and rapidly frozen. This control plasma may be used to monitor the performance of coagulation assays for the following parameters: fibrinogen (Clauss Method), coagulation factors II, V, VII, VIII, IX, X, XI and XII, anti-thrombin, protein C and protein S.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision testing for the VisuCal-F frozen calibrator plasma and the VisuConF frozen normal and abnormal control plasmas was performed as part of the value assignment process by running each lot of plasma in replicates of five over 4 days $( \mathrm { n } { = } 2 0 )$ ). The intra-assay and inter-assay precision results for each analyte were calculated per NCCLS (CLSI) Guideline EP05-A2. Results were considered valid if predefined acceptance specifications of $\% \mathrm { C V }$ of $65 \%$ or $1 5 \%$ , depending on the analyte tested, were achieved for intra and inter-assay precision.

$b$ . Linearity/assay reportable range: Not Applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability: Calibrator value assignment is traceable to SSC/ISTH secondary coagulation standard, where available, which is calibrated against WHO International standards.

Stability: Open-vial stability of the thawed calibrator and control plasmas was performed on two validation lots for each product. After thawing, plasmas were tested for the indicated analytes, stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ in the original vial and retested at 4 hours and 8 hours after initial testing. Antigen assays were only performed if activity assays showed a significant decrease over time. Plasmas were considered stable if the following specifications were met:

Results at 4 and 8 hour time points are:

• Within $\pm 1 0 \%$ of the time 0 result for PT and aPTT Within $\pm 1 5 \%$ of the time 0 result for fibrinogen, factors II to XII, antithrombin, protein C and protein S

Calibrator Value Assignment: Assigned values for all analytes for each lot of calibrator plasma were determined by testing 20 vials over 4 days, five vials per day and calculating the mean value of the determinations.

Controls Value Assignment: For each lot of normal and abnormal control plasma, ranges were assigned to the various analytes by testing 20 vials over 4 days, five vials per day and calculating the mean $\pm 2$ standard deviations.

d. Detection limit: Not Applicable   
e. Analytical specificity: Not Applicable   
$f .$ Assay cut-off: Not Applicable

2. Comparison studies: a. Method comparison with predicate device: Not Applicable b. Matrix comparison: Not Applicable

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable   
b. Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off:

Not Applicable

5. Expected values/Reference range:

The expected values for the VisuCal-F Calibrator are demonstrated in the table below.

<table><tr><td rowspan=1 colspan=2>Parameter</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Instrument</td></tr><tr><td rowspan=1 colspan=2>Fibrinogen (Clauss)</td><td rowspan=1 colspan=1>3.41 g/L</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor II (activity)1</td><td rowspan=1 colspan=1>89%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor V (activity)</td><td rowspan=1 colspan=1>105%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor VII (activity)</td><td rowspan=1 colspan=1>105%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor VIII (activity)(clotting)</td><td rowspan=1 colspan=1>78%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor IX (activity) 1</td><td rowspan=1 colspan=1>113%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor X (activity) 1</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor XI (activity)1</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Factor XII (activity) 2</td><td rowspan=1 colspan=1>118%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>α-2- antiplasmin (activity)3</td><td rowspan=1 colspan=1>123%</td><td rowspan=1 colspan=1>ACL7000</td></tr><tr><td rowspan=1 colspan=2>Antithrombin (activity) </td><td rowspan=1 colspan=1>107%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=2>Plasminogen (activity) 3</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>ACL7000</td></tr><tr><td rowspan=2 colspan=1>Protein C</td><td rowspan=1 colspan=1>activity1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=1>antigen</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Microplate reader</td></tr><tr><td rowspan=2 colspan=1>Protein S</td><td rowspan=1 colspan=1>activity</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>STA Compact</td></tr><tr><td rowspan=1 colspan=1>antigen</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Microplate reader</td></tr><tr><td rowspan=2 colspan=1>vWF</td><td rowspan=1 colspan=1>antigen</td><td rowspan=1 colspan=1>105%</td><td rowspan=1 colspan=1>Microplate reader</td></tr><tr><td rowspan=1 colspan=1>RistocetinCofactor1</td><td rowspan=1 colspan=1>63%</td><td rowspan=1 colspan=1>BCS</td></tr></table>

1 Calibrated against SSC/ISTH reference standard 2 Calibrated against Standard Human Plasma Dade Behring 3 Calibrated against Cryocheck Normal Reference Plasma Precision Biologic

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.